The Trump administration has reached a deal with two drug makers to lower prices of popular GLP-1 diabetes medications for Americans on Medicare and Medicaid as well as for those who purchase the drugs on the administration’s forthcoming TrumpRx web site.
The deal will also see Medicare and Medicaid expand coverage for the medications to permit Americans with certain medical conditions or a body mass index above certain thresholds to receive the injections as treatments for obesity and other serious conditions.